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a b s t r a c t
Background: Breast cancer incidence increases with age and real-world data is essential to guide pre-
scribing practices in the older population. The aim of this study was to collect large scale real-world data
on tolerability and efficacy of palbociclib þ AI in the first line treatment of ERþ/HER2-advanced breast
cancer in those aged 75 years.
Methods: 14 cancer centres participated in this national UK retrospective study. Patients aged 75 years
treated with palbociclib þ AI in the first line setting were identified. Data included baseline de-
mographics, disease characteristics, toxicities, dose reductions and delays, treatment response and sur-
vival data. Multivariable Cox regression was used to assess independent predictors of PFS, OS and
toxicities.
Results: 276 patients met the eligibility criteria. The incidence of febrile neutropenia was low (2.2%). The
clinical benefit rate was 87%. 50.7% of patients had dose reductions and 59.3% had dose delays. The 12-
and 24- month PFS rates were 75.9% and 64.9%, respectively. The 12- and 24- month OS rates were 85.1%
and 74.0%, respectively. Multivariable analysis identified PS, Age-adjusted Charlson Comorbidity Index
(ACCI) and number of metastatic sites to be independent predictors of PFS. Dose reductions and delays
were not associated with adverse survival outcomes. Baseline ACCI was an independent predictor of
development and severity of neutropenia.
* Corresponding author.
E-mail address: salma.elbadri@nhs.net (S. El Badri).
Contents lists available at ScienceDirect
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Conclusion: Palbociclib is an effective therapy in the real-world older population and is well-tolerated
with low levels of clinically significant toxicities. The use of geriatric and frailty assessments can help
guide decision making in these patients.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Breast cancer is the most common cancer in the UK and ac-
counts for 21% of all cancer diagnoses in females aged75 years [1].
The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors
into routine clinical practice has changed the paradigm of man-
agement of oestrogen receptor-positive (ERþ), human epidermal
growth factor receptor 2 negative (HER2-) advanced breast cancer.
However, with the older population representing a growing pro-
portion of these patients, it is important to carefully evaluate the
available evidence in this group, considering they are under-
represented in clinical trials. Those older patients included in tri-
als tend to be highly selected with a lower risk profile compared to
the real-world population, with that disparity increasing with
increasing age [2,3]. It is, therefore, necessary to collate real-world
data to fill the gaps in knowledge, consolidate the evidence and
inform clinicians who prescribe CDK4/6 inhibitors to these older
patients.
Three CDK4/6 inhibitors are currently approved in the UK and
are being used in clinical practice in first line with an aromatase
inhibitor (AI) and second line with fulvestrant: palbociclib, abe-
maciclib and ribociclib. Although these agents have some over-
lapping toxicities, specific side effects are unique to, or more
frequently encountered with, certain agents. This makes it difficult
to group them together under one umbrella when analysing safety
or efficacy data. Given that palbociclib was the first agent to be
approved and is one of the most frequently prescribed drugs in its
class in the UK, it was selected as the agent of choice for this study.
Palbociclib is an orally active and highly selective reversible
inhibitor of CDK 4 and 6 that blocks the transition from G1 to S
phase of the cell cycle [4]. It was available for use in the UK from
September 2017 on the patient access scheme and approved by the
National Institute for Health and Care Excellence (NICE) in
December 2017 for use in combinationwith an AI for the treatment
of ERþ/HER2-advanced breast cancer in the first-line setting [5].
This approval followed on from the results of the PALOMA-2 study
which showed a significant improvement in progression-free sur-
vival (PFS) with palbociclib combined with letrozole compared
with letrozole alone [6]. Out of the 444 patients included in the
PALOMA-2 trial, only 48 were aged 75 years.
A pooled analysis from the PALOMA studies included 83 patients
aged 75 years who received palbociclib across the 3 trials and it
was found to be a safe and effective treatment in this population
but noted higher rates of myelosuppression among patients aged
75 years [7]. Another pooled analysis of phase III randomised
controlled trials examined the efficacy and safety of different CDK
4/6 inhibitors in combination with an AI in 198 women aged 75
years which showed higher rates of toxicity and dosemodifications.
There was a decrease from baseline in quality-of-life measures in
women irrespective of treatment with either combination therapy
or single agent AI, suggesting no significant impact of CDK4/6 in-
hibitors on quality of life [8]. The authors recognised the limitations
of the differential toxicity profiles of the three CDK4/6 inhibitors.
Real-world studies have looked at the efficacy and safety of
palbociclib, some of which focussed on the older patient group. A
French real-world study of palbociclib in patients aged over 70
years (PALOMAGE) reported a lower incidence of grade 3/4 adverse
events in those aged 80 years [9]. A US retrospective analysis
included 92 patients aged 70 years treated with palbociclib and
reported significantly higher rates of dose reductions and delays in
patients 70, but with no detriment to survival outcomes [10].
Another US retrospective study showed that a lower starting dose
wasmore common is those aged75 years and linked this toworse
survival outcomes [11].
The in-patient secondary care cost burden, i.e. the costs asso-
ciated with hospital admissions, is another important consider-
ation in these patients given their frailty and higher comorbidity
burden. The rate of hospitalisation for chemotherapy-related tox-
icities in older patients with breast cancer increases with increasing
comorbidity score [12], and it is important to look at how this
compares to palbociclib-related hospitalisation rates and costs in
this population.
This national UK study was designedwith the aim of collecting a
significantly large scale real-world dataset of patients aged 75
years to evaluate the tolerability, efficacy and secondary care in-
patient burden in the National Health Service (NHS) when palbo-
ciclib is used in combinationwith an AI in the first-line treatment of
elderly patients with ERþ/HER2-advanced breast cancer. ACCI was
used to assess the baseline comorbidity burden in this population
and its impact on treatment and tolerability. This study will add to
the existing body of evidence from clinical trials and smaller real-
world datasets which will help guide prescribing practices and




This was a national multicentre retrospective study open to sites
across the UK with 14 cancer centres participating. The study
protocol was approved by the Clinical Effectiveness Unit at Sheffield
Teaching Hospitals NHS Trust, with the required approvals for data
storage and transfer obtained from the Information Governance
department. The project leads in Sheffield designed an Excel
spreadsheet and disseminated it to centres for data collection. Data
was collected from medical records and systemic anti-cancer
therapy prescribing systems/pharmacy records. Data was trans-
ferred in a pseudonymised state. The participating centres were
required to register the study in their respective hospital trusts and
follow the local policies for data storage and transfer.
2.2. Study population
Patients aged 75 years with a confirmed diagnosis of ERþ/
HER2-advanced breast cancer who have received at least one cycle
of palbociclib in combination with an AI starting from the first
availability of Palbociclib in the UK on clinical trials (March 2016) to
data close in Feb 2021 including patient treated on early access to
medicines schemes and standard NHS England funding through the
Cancer Drugs Fund. The 5 year period for data collection allowed
sufficient time for follow-up.
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2.3. Data source
Data extracted from medical records included age, Eastern
Cooperative Oncology Group (ECOG) performance status (PS),
concurrent regular medications, co-morbidities, weight, height,
total ER Allred score, de novo metastatic disease or recurrent dis-
ease, metastatic disease burden, number of in-patient admissions
during palbociclib treatment, duration of in-patient admission and
investigations performed, best radiological response to palbociclib,
reason and date of treatment discontinuation, date of disease
progression and date of death, where applicable.
ACCI has been used to assess the baseline comorbidity burden in
this population, which is calculated using weighted scores for a
range of comorbidities, adjusted for age. The comorbidities include
myocardial infarction, congestive heart failure, peripheral vascular
disease, cerebrovascular accident or transient ischaemic attack,
dementia, chronic obstructive pulmonary disease, connective tis-
sue disease, peptic ulcer disease, liver disease, diabetes mellitus,
hemiplegia, chronic kidney disease, leukaemia, lymphoma, ac-
quired immunodeficiency syndrome and solid organ malignancy
[13].
Data was also extracted from systemic anti-cancer therapy
(SACT) prescribing systems/pharmacy records at each cancer
centre. This included method of access to palbociclib, type of AI
used, date of start of palbociclib, starting dose, number of cycles
received, number of dose modifications, number of dose delays and
adverse events.
2.4. Outcome measures
The tolerability was assessed using the rates of dose reduction,
dose delay and adverse events; the latter categorized using Com-
mon Terminology Criteria for Adverse Events (CTCAE v5.0). The
reported adverse events during treatment with palbociclib were
classed as treatment-related; however, it is worth noting that
causality is difficult to ascertain in a retrospective study. For
instance, transaminitis resulting from progression of metastatic
liver disease may not be clearly distinguished from that related to
treatment, except that it is usually reversible if drug-related, and so
causality was defined by the clinical teams following patient
assessment and subsequent follow up.
Response measures included best radiological response and the
clinical benefit rate; defined as the rate of complete response,
partial response or stable disease for 24 weeks. Exploratory sur-
vival analysis included PFS; measured from the date of starting
palbociclib until disease progression, death or data censoring,
whichever occurred first, and overall survival (OS); measured from
the date of starting palbociclib until death or data censoring if still
alive. Given the variability in the timing of response assessments in
the real world, the response measures and PFS analysis are as close
an estimate as could be derived from a retrospective real-world
analysis.
In-patient secondary care burden due to adverse events was
calculated by using costs per day for non-elective inpatient ad-
missions relating to the relevant healthcare related group (HRG)
within the National Reference Cost collection. Where there were
multiple HRG groups relating to a particular type of adverse event,
an activity weighted mean cost per day was calculated [14]. The
cost of X-rays and blood tests was derived from direct access ser-
vices. The cost of a CT is based on the National Reference Cost for a
scan of three areas, with contrast (RD26Z, taken as an activity
weighted average across direct access, outpatients and ‘other').
2.5. Statistical analysis
Descriptive and inferential statistical analyses were performed.
Descriptive statistics included tabular summaries of data. Contin-
uous variables were reported as median (range). Categorical vari-
ables were reported as absolute numbers (percentages). Median,
12- and 24-month PFS and OS time-to-event outcomes were
calculated using Kaplan-Meier estimates.
Multivariable regression models via the forced-entry procedure
were conducted to assess which baseline variables, selected on the
basis of clinical expertise, were independent predictors of out-
comes. Specifically, multivariable Cox proportional hazards
regression analyses were performed to determine the associations
of age, PS (0e1 or 2), starting dose (125 mg or <125 mg), dose
reduction (yes or no), dose delay (yes or no), baseline ACCI and the
number of metastatic sites with PFS and OS. Four cumulative odds
ordinal logistic regression models with proportional odds were run
to determine the effects of age, PS, baseline ACCI and number of
metastatic sites on the onset and severity of neutropenia, throm-
bocytopenia, anaemia and fatigue.
Patients with missing data for a covariate or outcome measure
were excluded from the analysis of that outcomemeasure. Analyses
were performed using SPSS (version 26.0, IBM Corporation,
Armonk, NY, USA) or STATA (version 16.1, StataCorp LLC, College
Station, TX, USA) statistical software. All P-values were 2-sided and
a P-value of <0.05 was considered statistically significant.
3. Results
Fourteen cancer centres from across the UK participated in this
study with data collection completed in February 2021. 276 pa-
tients met the eligibility criteria. Median follow-up time from
starting palbociclib was 23.1 months. The baseline demographics
are summarised in Table 1. The median age of patients was 78
(range 75e92) years. 79% of patients had an ECOG PS of 0e1 and
19.6% had a PS of 2. ACCI scores were calculated using age and
recorded comorbidities with higher score reflecting higher co-
morbidity burden. 53.1% of patients had visceral metastases and
33.7% had bone-only disease. 88% of patients started palbociclib at
the standard dose of 125 mg.
The median duration of treatment with palbociclib and AI was
15.7 months (range 1e43.4 months). Treatment was discontinued
in 138 patients (50%); this was due to disease progression in 65
(47.1%) patients, toxicity in 36 (26.1%) and death in 22 (15.9%) pa-
tients. At least 54 patients had treatment interrupted due to the
perceived risks during the COVID-19 pandemic; 35 patients have
subsequently restarted treatment. As data collection was started
prior to the pandemic, data on treatment interruption was not
specifically collected and these numbers are derived from addi-
tional notes provided by centres.
The most common toxicities were neutropenia, followed by
fatigue, anaemia and thrombocytopenia. Only six patients (2.2%)
had febrile neutropenia. Table 2 shows the common toxicities re-
ported with palbociclib in this patient group using the CTCAE v5.0
grading system.
140 patients (50.7%) required a dose reduction, with the ma-
jority of these occurring in the first 3 cycles (57.9%). The most
common reasons for dose reduction were neutropenia (54.3%), fa-
tigue (21.4%) and thrombocytopenia (5%). 163 patients (59.3%)
required at least one dose delay. The most common reasons for
dose delay were neutropenia (66.3%), infection (10.4%) and fatigue
(6.7%).
Out of the 276 patients, 22 (9.6%) required hospital admission
due to toxicity. The median duration of in-patient stay was 6 days
(range 1e76 days) and the mean was 11 days (SD: 17 days). The
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average annual cost per patient for hospital admission due to
toxicity was £342.16. Given the small sample size and degree of
imputation in calculating cost, this is an estimated average. The
calculation incorporated the cost of hospital admissions, blood tests
and imaging. The precise toxicity necessitating admission to hos-
pital was specified for 11 patients; 7 of thesewere due to infections.
The best radiological response was complete response in five
patients (2.0%), partial response in 81 (32.9%) and stable disease in
135 (54.9%), with 25 patients (10.2%) having progressive disease.
Thirty patients did not have a recorded radiological response
assessment. The clinical benefit rate at 24 weeks was 87%. The PFS
rates at 12 and 24 months were 75.9% and 64.9%, respectively. The
OS rates at 12 and 24 months were 85.1% and 74.0%, respectively.
Kaplan-Meier curves for PFS and OS were plotted with patients
grouped based on whether they experienced a dose delay or not
(Fig. 1); log-rank tests demonstrated significant differences in sur-
vival distributions for both PFS and OS (p < 0.001).
Multivariable Cox regression identified increased PS, fewer dose
delays, increased ACCI and higher number of metastatic sites to be
independent adverse predictors of PFS. Significant adverse pre-
dictors of OS were increased PS, fewer dose reductions, fewer dose
delays, and increased number of metastatic sites. A summary of
multivariable Cox regression results for PFS and OS, including
hazard ratios (HRs) and 95% confidence intervals (CIs), are dis-
played in Table 3.
For the toxicity analysis, only baseline ACCI was an independent
predictor of onset and severity of neutropenia, odds ratio
(OR) ¼ 0.760 (95% CI, 0.597 to 0.968). PS was the only independent
predictor of the onset and severity of thrombocytopenia and fa-
tigue with the odds of increasing severity for patients with
PS ¼ 0e1 being 0.412 (95% CI, 0.228 to 0.748; p ¼ 0.004) and 0.515
(95% CI, 0.289 to 0.917; p ¼ 0.024) times that of patients with
PS ¼ 2e4, respectively. No variable was statistically associated with
anaemia.
4. Discussion
Palbociclib is the first in class CDK4/6 inhibitor approved for use
in patients with advanced ERþ/HER2-breast cancer. Given the
under-representation of the older population in clinical trials, real-
world data is crucial to bridge that gap in knowledge. This national
multi-centre retrospective UK study provides the largest known
dataset of patients aged 75 years treated in the NHS with
palbociclib þ AI in the first line setting, with a total of 276 patients
included.
In this study, 19.6% of patients had a PS of 2 or more, in contrast
to only 2% of patients included in the PALOMA-2 trial receiving
palbociclib. This is more reflective of the broader real-world pop-
ulation, and more so in the older patients. The proportion of elderly
patients presenting with de novo metastatic disease in this study is
comparable to that seen in other studies of CDK4/6 inhibitors
[6,8,15e17]. ACCI was used to assess the comorbidity burden using
an established scoring system that includes age and comorbidities
with higher scores reflecting higher comorbidity burden. The ma-
jority of patients started palbociclib at the standard dose of 125 mg,
29.5% of these patients had an ACCI >10. 32 patients (11.6%) started
at a lower dose of 100 mg or 75 mg, 46.9% of these had an ACCI >10.
This reflects a tendency to starting at a lower dose for those with a
higher comorbidity burden. None of the patients starting at a lower
dose had a subsequent dose escalation. Given the small number of
patients starting at a lower dose, it was not possible to assess the
effect of lower starting dose on efficacy. Recent results from the US
real-world study by Patt et al. (n ¼ 813) showed that lower starting
doses were more prevalent in patients over 75 years (38.5% vs
17.1%) with resulting lower real-world PFS (18.6 months vs 27.8
months) and treatment responses (40.4% vs 54.0%) [11]. Taken
together with our data which suggests subsequent dose reductions
Table 1
Baseline demographics and clinical characteristics.
Demographic N (%)











Not recorded 3 (1.1)
BMI
underweight <18.5 4 (1.4)
normal 18.5e24.9 78 (28.2)
overweight 25e29.9 77 (27.9)
obesity 30 56 (20.3)
Not recorded 61 (22.1)
ER status (Allred score)
strongly-positive (score 6e8) 257 (93.1)
weakly-positive (score 3e5) 7 (2.5)
Not Recorded 12 (4.3)
Burden of metastatic disease
visceral metastases e Yes 147 (53.1)
- No 127 (45.8)
Bone metastases e Yes 180 (65.0)
- No 95 (34.3)
Bone only metastases 93 (33.7)
Bone þ visceral metastases 85 (30.8)




3 or more 59 (21.7)
Presentation
De Novo metastatic disease 119 (43.1)
Recurrence 156 (56.5)
Not recorded 1 (0.4)




Not recorded 2 (0.7)
Starting dose of palbociclib
125 mg 243 (88.0)
100 mg 29 (10.5)
75 mg 3 (1.1)
Not recorded 1 (0.4)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group;
PS ¼ performance status; ACCI ¼ Age-adjusted Charlson Comorbidity
Index; BMI ¼ body mass index; ER ¼ oestrogen receptor; AI ¼ aromatase
inhibitor.
Table 2
Treatment-related adverse events e as per CTCAE v5.0
All grades - n (%) Grade 3 - n (%)
Neutropenia 223 (80.8) 128 (46.4)
Fatigue 148 (53.6) 10 (3.6)
Anaemia 125 (45.3) 8 (2.9)
Thrombocytopenia 102 (37.0) 7 (2.5)
Nausea 61 (22.1) 4 (1.4)
Stomatitis 59 (21.4) 1 (0.4)
Anorexia 53 (19.2) 0
Diarrhoea 51 (18.5) 3 (1.1)
Transaminitis 32 (11.6) 4 (1.4)
Vomiting 24 (8.7) 1 (0.4)
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and delays do not adversely affect efficacy, finding the maximum
tolerated dose early after treatment initiation should be considered
in this older population with subsequent dose modifications ac-
cording to toxicity.
With regards to tolerability in this patient group, neutropenia
was the most frequently occurring adverse event with all grade
neutropenia occurring in 80.8%. Although we cannot directly
compare to trial data, this was broadly similar to that seen in
PALOMA-2 (79.5%). Grade 3 neutropenia however was less
frequent (46.4% vs 66.5%). Febrile neutropenia was again uncom-
mon in the real-world older population (2.2%). There was a higher
frequency of fatigue, anaemia, thrombocytopenia and stomatitis in
this study as compared to PALOMA-2, whereas nausea, vomiting
and diarrhoea were less common. The rate of hospital admission
due to toxicity was relatively low (9.6%), again reflecting good
overall tolerability in the older population despite their frailty and
comorbidity burden. A review of Medicare data reported on the
rates of hospitalisation for chemotherapy-related toxicity in older
women with breast cancer in the US which were 12.3% and 13.2%
for patients with stage III and IV disease, respectively [12]. Direct
comparison of these results, however, is not possible, given the
different health systems and also the different time periods, taking
into consideration the advances in health care and management of
toxicities. A more recent US study of the rates of hospitalisation for
complications of systemic therapy reported 11.1% of patients with
breast cancer required hospital admission but this was not age- or
stage-specific [18]. The results of our real-world study reflect good
overall tolerability in the older population and are in keeping with
the safety analysis from the PALOMAGE French study which
showed palbociclib to be well-tolerated in this population with no
new safety signals identified [9].
The rate of treatment discontinuation due to toxicity was higher
in this real-world population (13%), in contrast to 9.7% in those
receiving palbociclib and letrozole in the PALOMA-2 trial. There
was also a significantly higher rate of dose reduction (50.7%),
compared to only 36% of patients in the trial requiring 1 dose
reduction. The rate of dose delays was lower compared to the trial
(59.3% vs. 67%). Despite the higher rates of treatment discontinu-
ation and dose reductions, the clinical benefit rate at 24 weeks was
comparable (87% vs 84.9% in PALOMA-2).
Looking at the in-patient secondary care burden, the hospital
admission rate due to toxicity was lower in this study compared to
that associated with chemotherapy [12], which reflects the better
tolerability of palbociclib. This is especially important in the older
population with multiple comorbidities. The average annual cost
per patient for palbociclib toxicity-related hospitalisation in our
study was £342.16. One other UK study has looked at the costs of
managing chemotherapy-associated toxicities in third line meta-
static breast cancer patients and showed average annual costs
ranging between £2621 and £2740 [19]. However, we are not able to
make a valid comparisonwith the results of that study as that work
is only available as a conference abstract and the methods are not
described in sufficient detail. Our own study also has limitations
which meant that unit costs were not related to specific toxicities
and we were restricted to costing only a small number of hospi-
talisations. Another limitation is the different timelines of the two
studies and the possible changes in management of toxicities
should be taken into account with a more cost-effective utilisation
of resources over time. However, given the importance of cost
analysis in the development of treatment guidelines, it is important
that future studies of toxicities incorporate this.
The survival results from this study looking at the 12 and 24-
month PFS and OS rates were also reassuring. Not surprisingly,
higher ACCI and higher metastatic disease burden as defined by
number of metastatic sites were associated with worse PFS. Inter-
estingly, and in keeping with results from other analyses, dose
Fig. 1. Kaplan-Meier survival plots demonstrating the association between dose delays and progression-free (left) and overall (right) survival.
Table 3
Summary of multivariable Cox regression results for PFS and OS. HR (95% CI) results for statistically significant predictors are in bold.
Outcome measure PFS OS
HR (95% CI) p-Value HR (95% CI) p-Value
Age (continuous) 0.975 (0.917e1.036) 0.413 1.015 (0.949e1.086) 0.655
PS (categorical): 0e1 as reference vs 2-4 3.132 (1.972e4.973) < 0.001 3.638 (2.159e6.130) < 0.001
Starting dose (categorical): 125 mg as reference vs < 125 mg 1.459 (0.685e3.104) 0.327 1.883 (0.722e4.912) 0.196
Dose reduction (categorical): no as reference vs yes 0.814 (0.507e1.304) 0.391 0.535 (0.309e0.927) 0.026
Dose delay (categorical): no as reference vs yes 0.425 (0.269e0.672) < 0.001 0.393 (0.232e0.665) 0.001
Baseline ACCI (continuous) 1.260 (1.033e1.536) 0.022 1.236 (0.990e1.543) .061
Number of metastatic sites (continuous) 1.491 (1.253e1.775) < 0.001 1.471 (1.201e1.801) 0.001
Abbreviations: ACCI ¼ Age-adjusted Charlson Comorbidity Index; CI ¼ confidence interval; HR ¼ hazard ratio; PFS ¼ progression-free survival; PS ¼ performance status;
OS ¼ overall survival.
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reductions and delays were not associated with worse survival
outcomes [10]. Dose delays were actually found to be associated
with longer PFS and OS in this real-world UK study; dose reductions
were associated with longer OS. These results are reassuring to the
prescribing clinicians as well as patients that de-escalation of pal-
bociclib dose or frequency does not negatively impact on efficacy;
however, the data here cannot claim superiority of disease out-
comes with dose delays/reductions due to the limitations of rela-
tively small patient numbers and this being a retrospective study
rather than a prospective controlled trial. Considering commonly
attributed favourable prognostic characteristics such as bone-only
disease and de novo presentation of disease, the group needing
dose delays had a similar proportion of bone-only disease
compared to those not needing a dose delay (36.6% vs 30.6%,
respectively) and the proportion of de novo disease was higher in
the group not requiring dose delays (51.4% vs 38.0%). The biological
rationale for the effect of dose delays and reductions on survival
outcomes is not clear but age-related changes in the pharmacoki-
netics and pharmacodynamics of drugs, including reduced hepatic
metabolism and renal excretion, and changes in cancer biology
with a relatively indolent disease in the older population, may all
result in efficacious dosing of drugs in these patients that is
different to the standard dosing in the younger population [20].
Increasing age does have a statistically significant effect on total
clearance of palbociclib from plasma (CL/F) and at an age of 74
years, CL/F was predicted to decrease by approximately 8%
compared to the value at 61 years [21]. This may, in itself, not be
considered a clinically relevant effect, but when considered in a
frailer population with polypharmacy, there could be an effect on
concurrent co-morbid conditions affecting all-cause mortality in a
population who may die with, rather than of, their breast cancer.
Another theory to consider is toxicity as a potential predictive
biomarker for response which is observed with other anticancer
drugs and would give a plausible explanation for those with dose
reductions and delays having better survival outcomes [22]. This
data should not change prescribing practice but is certainly hy-
pothesis generating and requires further consideration.
Looking at predictors for toxicity, increasing ACCI was an inde-
pendent significant predictive factor for onset and severity of
neutropenia, which would therefore be important to take into
considerationwhen considering patients suitable for longer follow-
up intervals on treatment. Good PS (0e1) was found to be a pre-
dictor of worse thrombocytopenia and fatigue which cannot be
clearly explained, however one speculation could be that those
with worse PS have more dose reductions and delays due to
alternative causes, which in turn could result in reduced incidence
and severity of thrombocytopenia and fatigue.
This large-scale study has shown palbociclib to be a well-
tolerated treatment in older patients with advanced ERþ/HER2-
breast cancer despite their frailty and comorbidity burden. Efficacy
outcomes were also consistent with no detriment to survival out-
comes despite higher rates of treatment discontinuation and dose
reduction. This is in keeping with the recommendations made by
the joint European Society of Breast Cancer Specialists and the In-
ternational Society of Geriatric Oncology (SIOG) taskforce which
recommends CDK4/6 inhibitors as a suitable treatment in older
patients given that efficacy is age independent as shown from the
pooled analyses of the landmark trials, though higher rates of
toxicity and dose modifications were acknowledged in those aged
75 years [23].
ACCI proved to be a significant predictor of PFS as well as for
development and severity of neutropenia in this study. The authors
acknowledge that ACCI only captures the comorbidity domain of
geriatric assessments but this was chosen as a surrogate as it is the
most consistently documented and readily available data for the
purposes of a widescale retrospective review within the NHS.
Comprehensive geriatric assessments are recommended by SIOG
and the importance of incorporating them in clinical trials and
prospective observational studies of CDK4/6 inhibitors was high-
lighted in a review paper by Battisti et al. [24,25]. The use of ACCI as
an independent predictor of survival and toxicity in elderly patients
receiving CDK4/6 inhibitors would need to be validated, but the
results from this study further reinforce the importance of using
baseline geriatric and frailty assessments to aid discussions and
monitoring on treatment.
Some of the limitations of this study have already been dis-
cussed. Other limitations to acknowledge given the retrospective
nature of data collection include the lack of a control group to allow
comparative efficacy, lower accuracy and inferior quality of data as
compared to clinical trials and the lack of comprehensive geriatric
assessments as discussed, although ACCI was used as a surrogate.
Another important limitation is the lack of data on quality of life
which is a key metric in this older population with limited life
expectancy. Nevertheless, this large UK real-world study adds to
the existing body of evidence and sheds light on potential predic-
tive factors for response and toxicity with palbociclib in the older
population, which would need to be explored further in prospec-
tive studies.
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